Article Sidebar

PDF
Date Published: 21/07/2021
Abstract Views: 858
Views PDF: 702
DOI: https://doi.org/10.51298/vmj.v501i2.504
Issue
Vol. 501 No. 2 (2021)
Section
Các bài báo
How to Cite
Duy Thông, V. ., & Thanh Hải, N. . (2021). INVESTIGATION ON THE PRESCIPTIONS FOR PATIENTS WITH HELICOBACTER PYLORI AT A HOSPITAL IN HO CHI MINH CITY. Vietnam Medical Journal, 501(2). https://doi.org/10.51298/vmj.v501i2.504

INVESTIGATION ON THE PRESCIPTIONS FOR PATIENTS WITH HELICOBACTER PYLORI AT A HOSPITAL IN HO CHI MINH CITY

Võ Duy Thông, Nguyễn Thanh Hải

Main Article Content

Abstract

Background: Helicobacter pylori (H. pylori) infection is the main cause of several upper gastrointestinal diseases. Tretment guidelines for H. pylori has been updated base on the antimicrobial resistance of H. pylori. Objective: Evaluate the appropriateness of drug use in prescriptions of patienst with H. pylori at a Hospital, Ho Chi Minh City. Materials and Methods: A cross – sectional study was conducted on prescriptions of outpatients diagnosed with H. pylori, in March 2021. Prescriptions were reviewed for data analysis including all information of patients, clinics and drug used. The appropriateness of precriptions was accessed based on the 2016 Maastricht V/Florence Consensus and the 2016 ASEAN Consensus. Results: There were 96 priscriptions of outpatients included in this study. The mean age of patients was 48 y.o, 59.4% was female. Bismuth quadruple therapy was the most commonly prescribed in patients (77.1%). The rate of prescriptions with at least one error was 29.2%. The common prescribing errors were inpropriateness in bismuth, metronidazole/tinidazole, and PPI dosage. The surgeons made a higher rate of prescribing errors than internal doctors.

Article Details

Keywords

prescription, medication error, outpatient

References

1. Eusebi L. H. et al. (2014), “Epidemiology of Helicobacter pylori infection”. Helicobacter, 19(1), pp.1-5.
2. Varocha M. et al. (2018), “Helicobacter pylori management in ASEAN: The Bangkok consensus report”. Journal of Gastroenterology and Hepatology, 33, pp. 37–56.
3. Malfertheiner P, et al. (2017), “Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report”. Gut, 66, pp.6–30.
4. Pounder RE et al. (1995), “The prevalence of Helicobacter pylori infection in different countries”. Aliment Pharmacol Ther, 9(2), pp. 33.
5. Torres J, et al. (1998), “A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico”. J Infect Dis, 178, pp. 1089.
6. Binh TT, et al. (2012), “The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam”. J Clin Gastroenterol, 47(3), pp. 233-238.
7. Yamaoka Y, et al. (2015), “Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective”. Molecules (Basel, Switzerland), 20(4), pp. 6068–6092.
8. Malekzadeh R, et al. (2014), “Helicobacter pylori eradication in West Asia: a review”. World journal of gastroenterology, 20(30), pp. 10355–10367.
9. Choi M, et al. (2021), “Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020”. Gut Liver, 15(2), pp. 168-195.